ArticleMaterials today. Bio2026
Facile synthesis of amorphous coordinated metal-drug frameworks for cancer immunotherapy.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phosphoinositide kinase containing FYVE-type zinc finger (PIKfyve) inhibitors show potential immunomodulatory activity but suffer from poor tumor targeting and formulation challenges. Herein, we screened a series of PIKfyve inhibitors and engineered selected PIKfyve inhibitor into amorphous metal-drug frameworks (aMDFs) through coordination chemistry between pyridine/imidazole moieties and tailored metal nodes verified by theoretical simulations and nuclear magnetic resonance spectroscopy. The resulting aMDFs showed enhanced stability and processability, enabling efficient encapsulation into solid lipid NPs (HF@SLN). In both orthotopic and subcutaneous murine pancreatic cancer models, HF@SLN demonstrated superior tumor growth inhibition over free PIKfyve inhibitors. HF@SLN treatment was associated with increased transcription factor EB (TFEB) expression, accompanied by enhanced cytotoxic T cell infiltration and improved antitumor immune responses in both murine and human pancreatic tumor samples. This study demonstrates the feasibility of employing carrier-free aMDFs for the formulation and delivery of pyridine- and imidazole-containing therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.